Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH-2007-2.3.2-6 | Award Amount: 15.92M | Year: 2008
There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, peptides and antibodies (Abs) to fusion-intermediate conformations of gp41 leads to an inhibition of HIV cell entry. The principal aim of this project is to exploit this information by establishing a platform where gp41-derived vaccine candidates will be designed to elicit neutralising Abs. Several families of immunogens which mimic gp41 in its fusion intermediate conformations are already available and others will be designed using modelisation approaches. Candidates will be submitted to a thorough biophysical characterisation followed by a preclinical development in order to identify the most promising for clinical evaluation. A crucial selection parameter is the capacity of antigens to elicit neutralising Abs using internationally standardized assays. Since sexual transmission accounts for more than 90% of HIV infection, the capacity of Abs to inhibit infection at the mucosal level will also be determined. This cross-disciplinary project gathers top European scientists with expertise in protein engineering and characterisation, adjuvantation, formulation for systemic and mucosal delivery, evaluation of functional antibody response, efficacy testing in animal models, medium to large scale vaccine production as well as conduct of clinical trials in both developed and third-world countries. In contrast to previous more empirical attempts, this project is based on the rational exploitation of the knowledge on the mechanism of HIV entry and is thus a promising approach to generate a protective vaccine. It will be the first European project targeting intermediate conformations of gp41 and it could complement/synergize other international strategies focusing on the membrane proximal region of gp41 or gp140 trimer to induce neutralising Abs or aiming at reducing the viral load by eliciting a cellular immunity against HIV.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: KBBE-2007-3-2-07 | Award Amount: 8.23M | Year: 2009
The PolyModE project convenes an international, interdisciplinary, and intersectorial consortium to identify, characterise, and optimise novel polysaccharide modifying enzymes, and to develop robust fermentation strategies for their large-scale production, to exploit the potential of biopolymers for food, pharmaceutical, cosmetic, and technical applications. We have selected the six complex carbohydrates with the highest current market share or expected future market potential, namely alginate, carrageenan, chitosan, glycosaminoglycan, pectin, and xanthan gum. For each of these, the industrial partners have identified those enzymes which will answer to the most pressing needs or offer the most promising potential for improved production of polysaccharides with novel physico-chemical properties and biological functionalities. Primary targets will be alginate epimerases, carrageenan sulfatases, chitosan de-acetylases, glycosaminoglycan sulfatases, pectin de-acetylases, and xanthan gum de-acetylases. These enzymes together with secondary target enzymes, e.g. sequence specific lyases and hydrolases, will allow the generation and analysis of polymers and oligomers with novel, non-random patterns of modification. Two parallel approaches will be followed for each type of polysaccharide modifying enzyme, namely a knowledge-based genomic approach and a broad, un-biased metagenomic approach, e.g. using soil or sludge samples with a history of contact with the polysaccharide in question. A pipeline of three levels of fermentation systems will be established, ranging from lab-scale innovative expression systems with features shaped according to the specific characteristics of our target enzymes, through medium-scale, novel and unusual fermentation systems provided by a number of SME with highly specialised knowledge and expertise in developing and using such systems, to the established large-scale fermentation systems and facilities of market leaders in White Biotechnology.
Agency: European Commission | Branch: FP7 | Program: CSA-SA | Phase: SiS.2012.1.2-1 | Award Amount: 4.59M | Year: 2013
Synthetic biology (SynBio) offers huge potential for applications in energy, health and the environment. It also brings with it various challenges such as regulatory issues of biosafety, biosecurity and intellectual property rights, as well as potential environmental and socio-economic risks in developing countries. As yet, however, there is scant public knowledge about the technology. It is thus essential to establish an open dialogue between stakeholders concerning SynBios potential benefits and risks and to explore possibilities for its collaborative shaping on the basis of public participation. SYN-ENERGY will organise a wide range of mobilisation and mutual learning processes relating to these challenges. Besides a number of well-established European and international networks, the consortium encompasses and can mobilise a wide variety of stakeholders from science, industry, civil society, policy, education, art and other areas. Learning processes will contribute to a better understanding of SynBio research and innovation and to enhanced public engagement, while at the same time stimulating reflection on novel approaches to an inclusive governance framework that is capable of fostering responsible research and innovation. The processes will involve citizens and specific publics through well-established and innovative means of engagement, and will support the convergence of stakeholders and perspectives. Activities will be structured by four platforms, highlighting SynBios future, public, cultural and research & innovation perspectives. The iterative mutual learning process within SYN-ENERGY will be open to change in order to accommodate the dynamics of an emergent field. By dint of its approach, design and consortium, SYN-ENERGY will be a Science in Society activity with significant impact, raising public awareness of SynBio and yielding benefits for involved stakeholders, public discourse and European policy making in an international context.
Agency: European Commission | Branch: FP7 | Program: CP-TP | Phase: KBBE.2013.3.6-01 | Award Amount: 11.70M | Year: 2013
The Nano3Bio project convenes a consortium of world renowned experts from 8 EU universities, 1 large company, and 14 SME, to develop biotechnological production systems for nanoformulated chitosans. Chitosans, chitin-derived polysaccharides varying in their degree of polymerisation (DP), degree of acetylation (DA), and pattern of acetylation (PA), are among the most versatile and most promising biopolymers, with excellent physico-chemical and material properties, and a wide range of biological functionalities, but their economic potential is far from being exploited due to i) problems with reproducibility of biological activities as todays chitosans are rather poorly defined mixtures, and ii) the threat of allergen contamination from their typical animal origin. The Nano3Bio project will overcome these hurdles to market entry and penetration by producing in vitro and in vivo defined oligo- and polymers with controlled, tailor-made DP, DA, and PA. Genes for chitin synthases, chitin deacetylases, and transglycosylating chitinases/chitosanases will be mined from different (meta)genomic sources and heterologously expressed, the recombinant enzymes characterized and optimized by protein engineering through rational design and molecular evolution, e.g. targeting engineered glycosynthases. These enzymes and genes will be used for in vitro and in vivo biosynthesis in microbial and microalgal systems, focusing on bacteria and diatoms. The bioinspired chitosans will be formulated into biomineralised hydrogels, nanoparticles, nanoscaffolds, etc., to impart novel properties, including by surface nano-imprinting, and will be bench-marked against their conventional counterparts in a variety of cell based assays and routine industrial tests for e.g. cosmetics and pharma markets. The process will be accompanied by comprehensive life cycle assessments including thorough legal landscaping, and by dissemination activities targeted to the scientific community and the general public.
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH-2009-2.3.2-4 | Award Amount: 15.44M | Year: 2010
Despite significant effort over the past decade to design and implement new vaccines strategies against HIV, no one has met its promise to prevent infection and/or to reduce viral load until reaching eradication of the HIV reservoir. To reach this goal, a translational research is critical to propose innovative approaches for an HIV vaccine enhancing broadly cross-reactive mucosal, humoral and cellular immune responses specific to HIV antigens. Composed by 13 partners from 5 European countries and 2 International Cooperation countries, the CUTHIVAC consortium gathers knowledges and cutting-edge technologies in vaccinology and HIV diseases to raise the challenge of developing a new HIV strategy. The CUTHIVAC approach is based on innovative transcutaneous and/or mucosal needle-free vaccination methods in a perspective that new vaccine candidates will redirect immune response toward cytotoxic CD8 and mucosal humoral responses. The trust of the project derives from the proof-of-concept that combination of routes of immunization and delivery systems will shape the immune responses towards its protective arms against HIV. Clinical trials will be implemented with last cutting-edge generation of HIV DNA-GTU candidate applied by transcutaneous, intradermal routes and/or mucosal administration of HIV-envelop protein-based vaccine. Large efforts will be positioned on the new genetic design of HIV antigens and delivery systems for developed and developing countries. These new vaccines will be tested in innovative preclinical approaches with a special highlight on routes of vaccination that will be translated into 2nd round of clinical trials in a perspective that could help to prevent and eradicate HIV. Through its integrative and multidisciplinary approach, CUTHIVAC will therefore provide the basis for a novel approach in vaccination with a view to wide its application to other infectious diseases such as malaria and tuberculosis.
Geneart Ag | Date: 2012-09-14
The present invention relates to synthetic gag and gagpol genes optimized for high level expression via codon optimization and the uses thereof for the efficient generation of vector particles. The invention further relates to the generation of packaging cells and vaccines based on the synthetic gag and gagpol genes.
Geneart Ag | Date: 2010-03-01
The present invention relates to a method for identifying frameshift mutations in coding nucleic acid sequences.
Geneart Ag | Date: 2012-06-15
The invention relates to a method for optimizing a nucleotide sequence for expression of a protein on the basis of the amino acid sequence of the protein, in which for a particular region there is specification of a test sequence with m optimization positions on which the codon occupation is varied, a quality function being used to ascertain the optimal codon occupation on these optimization positions, and one or more codons of this optimal occupation being specified as codons of the optimized nucleotide sequence. These steps are iterated, with the codons of the optimized nucleotide sequence which are specified in the preceding steps remaining unchanged in subsequent iteration steps. The invention additionally relates to a device for carrying out this method.
Geneart Ag and Life Technologies | Date: 2013-04-04
The invention generally relates to compositions and methods for designing and producing functional DNA binding effector molecules and associated customized services, tool kits and functional assays. In some aspects, the invention provides methods and tools for efficient assembly of customized TAL effector molecules. Furthermore, the invention relates to uses of TAL effector molecules and functional evaluation of such TAL by, for example, customized assays.
Geneart Ag | Date: 2011-12-20
The present invention relates to reading-frame-correct fragment libraries, methods for their production, and the use of the fragment libraries for selection of functional polypeptide variants with improved properties.